Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents

PHASE4CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

April 30, 2015

Conditions
Immune Response to Influenza VaccineInfluenza A Virus InfectionInfluenza B Virus Infection
Interventions
BIOLOGICAL

LAIV

Licensed and approved Live Attenuated Influenza Vaccination (LAIV) will be preferentially given to all children aged 5-8 years old as recommended by Advisory Committee on Immunization Practices. A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given LAIV will be used. The rest of the children aged 9-17 years old will receive IIV.

BIOLOGICAL

IIV

"A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given IIV will be used. The rest of the children 9-17 years old will receive LAIV.~\[Note: Although we do not anticipate exhausting the supply of LAIV, should this occur, children aged 5-8 will be offered IIV as it is also approved in this age group and should be used if LAIV is unavailable.\]"

Trial Locations (1)

54449

Marshfield Clinic - Marshfield Center, Marshfield

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

collaborator

University of Wisconsin, Madison

OTHER

lead

Marshfield Clinic Research Foundation

OTHER

NCT02250274 - Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents | Biotech Hunter | Biotech Hunter